Intuitive Surgical (ISRG): Strong Business, Risky Stock
💡 Puntos Clave
ISRG's business is thriving, but its sky-high valuation creates significant risk for new investors.
What Happened with Intuitive Surgical?
Intuitive Surgical (ISRG) reported exceptional fourth-quarter and full-year 2025 results, showcasing a business firing on all cylinders. Revenue for Q4 surged 19% year-over-year to $2.9 billion, contributing to a full-year revenue increase of 21% to $10.1 billion. This growth was fueled by a robust 18% increase in worldwide procedure volume for its da Vinci and Ion platforms.
The company also demonstrated strong hardware demand, placing 532 da Vinci surgical systems in the quarter, up from 493 a year ago. This pushed the global installed base to over 11,100 systems, cementing its leadership in robotic-assisted surgery. CEO Dave Rosa highlighted the year's success, noting over 3.1 million da Vinci procedures performed in 2025.
Despite these impressive operational results, the investment thesis is complicated by the company's guidance for 2026. Management expects worldwide da Vinci procedure growth to decelerate to a range of 13% to 15%. While still solid double-digit growth, this marks a step down from the 18% growth achieved in 2025.
The core conflict for investors is that this great business performance is set against a sky-high stock valuation. The company is executing flawlessly, but the stock price already reflects a tremendous amount of future success.
Why This Matters for Investors
This news matters because it highlights the classic investment dilemma of a wonderful business at a questionable price. Intuitive Surgical's operational excellence is undeniable, with strong recurring revenue from its massive installed base and a long runway for international expansion.
However, the stock's valuation introduces significant risk. With a market cap of about $175 billion and a price-to-earnings ratio of approximately 63, ISRG is priced for near-perfect execution. This leaves little margin of safety if growth decelerates faster than expected or if market sentiment shifts.
The guidance for slower procedure growth in 2026 is particularly concerning given the current valuation premium. Even if the company beats its typically conservative guidance, the stock appears expensive relative to its growth prospects. This creates vulnerability to a valuation multiple compression.
For current shareholders, the strong underlying business fundamentals provide reasons to hold, but new investors face the risk of overpaying for future growth that may already be priced in. The stock could suffer meaningful downside even if business performance remains strong simply because the market decides to assign a lower valuation multiple.
Bobby Insight
Hold if you own it, but wait for a better entry price if you don't.
Intuitive Surgical's business is exceptional with durable revenue streams and market leadership. However, the current valuation at 63x earnings leaves no room for error and significant downside risk if growth decelerates or market sentiment sours.
¿Cómo Me Afecta?
